NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Advent was a spin out from Cognate which manufactured DCVax-L during the trials and for that reason enabled consistency and the continuation of knowledge already acquired over years. It was brilliant for that to occur. As you likely know but will no doubt deny, shorts manufactured false light based financial havoc for both NWBO and Cognate when they blew up supplier based financing using the shares of NWBO as payment over years. Cognate ended having to sell itself off to CRL: https://ir.criver.com/news-releases/news-release-details/charles-river-laboratories-acquire-cognate-bioservices-create

Being able to retain that knowledge and information developed through Cognate for NWBO, and enable continuity for not the Specials Program and for full commercial licensing was brilliant and foiled shorts in a million unknown and untold ways.

What really pisses shorts off is that even when they blew things up, it created new opportunities to create a new structure for manufacturing, which I explained in my recent previous posts, that angers them to no end… it’s scalable, and NWBO will add automation shortly, apparently, and if you’re a short, that is so disappointing… so, we are playing the “Hey, look over there!” game again. That’s what all the focus on random old news is all about… Hey, don’t pay attention to the application with MHRA or that new PR about Flaskworks, look at this almost 20 year old PR, etc. wasting all of our time…

As for the so called “pumper” on the board, which is total garbage, you mean this gentleman:

https://thelifesciencesdivision.com/about/our-team/

Dr Navid Malik PhD MSc MBA ACSI
HEAD OF RESEARCH AND EXECUTIVE DIRECTOR
SENIOR MANAGER EMPLOYED

Navid is an award-winning stock picking analyst, (Starmine and Extel Rated) recognized Internationally for his work in the biotech sector.

Navid began his career at Williams de Broe – now part of the ING group, before moving to Collin Stewart, later as a partner at Matrix Corporate capital he won multiple awards in the sector.

Dr Malik headed up a number of smaller mid-cap broking firm healthcare franchises where he focused on marketing deals before co-founding The Life Sciences Division.

Image
Two Starmine Awards: Across Europe for stock picking pharmaceuticals and for healthcare UK & Eire (2011)

Navid has lead some of the largest European IPOs in the biotech sector, successfully floating companies onto the London Stock Exchange AIM market, as well as raising billions of dollars of capital. Dr Malik is an extel rated research analyst and continues to write extensive corporate and detailed thematic research on industry.

Dr Malik continues to serve as a Director or Non-executive Director of a number of life science companies.

It’s very easy to even find out why… if one wanted to find out…

17
APR
2012
Northwest Bio Welcomes New Additions To The Board Of Directors
Dr. Navid Malik and Mr. Jerry Jasinowski Bring Extensive Experience to the Board

Bethesda, Maryland, April 17, 2012 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) (NW Bio), a biotech company developing DCVax® personalized immune therapies for cancer, is pleased to announce the addition of Dr. Navid Malik and Mr. Jerry Jasinowski to the Company’s Board of Directors. These new members bring to the NW Bio Board longstanding, deep experience in the life sciences industry, advanced manufacturing, and corporate operations and governance.

Dr. Navid Malik is the Head of Life Sciences Research for Cenkos Securities Plc. in the UK, and has been one of the most influential analysts in the UK and Europe over the last decade, covering the life sciences industry worldwide. In 2011, Dr. Malik was awarded two Starmine Awards (awarded each year by Thomson Reuters and the Financial Times): Number One Stock Picker in the European Pharmaceutical Sector, and Number Two Stock Picker in the UK and Ireland Healthcare Sector. Dr. Malik has built life science teams and franchises at multiple large financial institutions in London, which completed IPOs and secondary stock offerings for small biotech and life sciences companies totaling over $700 million in recent years, and which also initiated research coverage on dozens of small life sciences companies in addition to covering large pharmaceutical, biologics and healthcare companies. Dr. Malik holds a PhD in Drug Delivery within Pharmaceutical Sciences, as well as degrees in Biomedical Sciences Research (M.Sc.) and Biochemistry and Physiology (B.Sc., joint honors). Dr. Malik also holds an MBA in finance.

You know, there is this amazing thing called Google and the Internet. You might learn how to use it.